Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Perioperative antithrombotic management is based on risk assessment for thromboembolism and bleeding, and recommended approaches aim to simplify patient management and minimize adverse clinical outcomes. Expand
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Oral anticoagulation is the optimal choice of antithrombotic therapy for patients with AF at high risk of stroke (CHADS(2) score of ≥ 2) and at lower levels of stroke risk, antithROMbotic treatment decisions will require a more individualized approach. Expand
The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage.
- J. Rosand, M. Eckman, K. Knudsen, D. Singer, S. Greenberg
- Archives of internal medicine
- 26 April 2004
Patients taking warfarin had a doubling in the rate of intracerebral hemorrhage mortality in a dose-dependent manner, and the data suggest that careful control of the INR, already known to limit the risk of warFarin-related ICH, may also limit its severity. Expand
Impact of health literacy on outcomes and effectiveness of an educational intervention in patients with chronic diseases.
OBJECTIVE Study impact of health literacy on educational intervention for patients "Living with Coronary Artery Disease." METHODS 187 patients were randomized to: VHS/DVD plus printed booklet; or… Expand
Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation
This decision model evaluated the cost-effectiveness of genotype-guided warfarin dosing for patients with nonvalvular atrial fibrillation and found that for the standard base case (a 69-year-old man with no contraindications to warfar in therapy and the current cost of genotyping of about $400), genotypes-guided dosing costs $170000 more per quality-adjusted life-year gained than standard warfarIn dosing. Expand
Moving the Tipping Point: The Decision to Anticoagulate Patients With Atrial Fibrillation
- M. Eckman, D. Singer, J. Rosand, S. Greenberg
- Circulation. Cardiovascular quality and outcomes
- 1 January 2011
Use of a more contemporary estimate of stroke risk shifts the “tipping point,” such that anticoagulation is preferred at a higher CHADS2 score, reducing the number of patients for whom anticoAGulation is recommended. Expand
Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians…
The AT9 methodology reflects the current science of evidence-based clinical practice guideline development, with reliance on high-quality systematic reviews, a standardized process for quality assessment of individual studies and the body of evidence. Expand
Can Patients Be Anticoagulated After Intracerebral Hemorrhage?: A Decision Analysis
Survivors of lobar ICH with atrial fibrillation should not be offered long-term anticoagulation, but patients with deep hemispheric ICH at particularly high risk for thromboembolic stroke or low risk of ICH recurrence might benefit from long- Term Anticoagulant therapy. Expand
Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers.
- M. D. de Perio, J. Tsevat, G. Roselle, S. Kralovic, M. Eckman
- Archives of internal medicine
- 26 January 2009
Use of the Q FT-G and QFT-GIT leads to superior clinical outcomes and lower costs than the TST and should be considered in screening non-BCG- vaccinated and BCG-vaccinated new HCWs for LTBI. Expand
Screening for prostate cancer. A decision analytic view.
The analysis does not support using PSA, TRUS, or DRE to screen asymptomatic men for prostatic cancer, and Screening may result in poorer health outcomes and will increase costs dramatically. Expand